What is the rationale for deploying a biologic such as dupilumab that inhibits type 2 cytokine signaling? What symptoms—itch, redness, and systemic burden—in pediatric and adolescent patients are ameliorated by targeted inhibition of IL-4 and IL-13?

What is the rationale for deploying a biologic such as dupilumab that inhibits type 2 cytokine signaling? What symptoms—itch, redness, and systemic burden—in pediatric and adolescent patients are ameliorated by targeted inhibition of IL-4 and IL-13?

What is the rationale for deploying a biologic such as dupilumab that inhibits type 2 cytokine signaling? What symptoms—itch, redness, and systemic burden—in pediatric and adolescent patients are ameliorated by targeted inhibition of IL-4 and IL-13?


Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Lawrence Eichenfield, MD

Lawrence Eichenfield, MD

Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital-San Diego
Vice Chair, Department of Dermatology
Professor of Dermatology and Pediatrics
UC San Diego School of Medicine